Literature DB >> 22624709

SMIP-016 in action: CD37 as a death receptor.

Lei Jin1, John C Cambier2.   

Abstract

CD37 is a tetraspannin that triggers cell death and is a potential therapeutic target in cancers. In this issue of Cancer Cell, Lapalombella et al. show that CD37 is tyrosine phosphorylated following engagement by a bivalent engineered antibody fragment that binds CD37 and activates both SHP-1-dependent apoptotic signaling and PI3K-AKT-mediated survival signaling.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID: 22624709      PMCID: PMC4363110          DOI: 10.1016/j.ccr.2012.04.034

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  Tetraspanins: molecular organisers of the leukocyte surface.

Authors:  Jacqueline M Tarrant; Lorraine Robb; Annemiek B van Spriel; Mark D Wright
Journal:  Trends Immunol       Date:  2003-11       Impact factor: 16.687

2.  Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC.

Authors:  Kuo-Ching Sheng; Annemiek B van Spriel; Kate H Gartlan; Mariam Sofi; Vasso Apostolopoulos; Leonie Ashman; Mark D Wright
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

3.  Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.

Authors:  Rosa Lapalombella; Yuh-Ying Yeh; Liwen Wang; Asha Ramanunni; Sarwish Rafiq; Shruti Jha; Justin Staubli; David M Lucas; Rajeswaran Mani; Sarah E M Herman; Amy J Johnson; Arletta Lozanski; Leslie Andritsos; Jeffrey Jones; Joseph M Flynn; Brian Lannutti; Peter Thompson; Paul Algate; Scott Stromatt; David Jarjoura; Xiaokui Mo; Dasheng Wang; Ching-Shih Chen; Gerard Lozanski; Nyla A Heerema; Susheela Tridandapani; Michael A Freitas; Natarajan Muthusamy; John C Byrd
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

4.  Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation.

Authors:  S Barrena; J Almeida; M Yunta; A López; N Fernández-Mosteirín; M Giralt; M Romero; L Perdiguer; M Delgado; A Orfao; P A Lazo
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

5.  Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions.

Authors:  K P Knobeloch; M D Wright; A F Ochsenbein; O Liesenfeld; J Löhler; R M Zinkernagel; I Horak; Z Orinska
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

Review 6.  TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.

Authors:  Tadeusz Robak; Pawel Robak; Piotr Smolewski
Journal:  Curr Opin Investig Drugs       Date:  2009-12

7.  Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.

Authors:  John D Hainsworth; Sharlene Litchy; John H Barton; Gerry Ann Houston; Robert C Hermann; James E Bradof; F Anthony Greco
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

8.  Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.

Authors:  Xiaobin Zhao; Rosa Lapalombella; Trupti Joshi; Carolyn Cheney; Aruna Gowda; Martha S Hayden-Ledbetter; Peter R Baum; Thomas S Lin; David Jarjoura; Amy Lehman; Donna Kussewitt; Robert J Lee; Michael A Caligiuri; Susheela Tridandapani; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2007-04-17       Impact factor: 22.113

Review 9.  The function of the protein tyrosine phosphatase SHP-1 in cancer.

Authors:  Chengyu Wu; Mingzhong Sun; Lijun Liu; G Wayne Zhou
Journal:  Gene       Date:  2003-03-13       Impact factor: 3.688

10.  The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity.

Authors:  Annemiek B van Spriel; Mariam Sofi; Kate H Gartlan; Alie van der Schaaf; Ineke Verschueren; Ruurd Torensma; Reinier A P Raymakers; Bruce E Loveland; Mihai G Netea; Gosse J Adema; Mark D Wright; Carl G Figdor
Journal:  PLoS Pathog       Date:  2009-03-13       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.